Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 18, Art. 30 (pp. 441-456)    |    2017       

»

Modern ideas about optimizing endocrine therapy for metastatic ER+/PR+, HER2 - breast cancer: literature review.

Kramchaninov М.М.

Saint-Petersburg scientific practical center of specialized kinds of medical care (oncological),
Saint-Petersburg, Russia.

Brief summary

Today, the metastatic breast cancer remains an incurable disease, and carried-out treatment is directed on prolonging the general survival, delaying disease progression and improving quality of life of patients. The hormone-positive breast cancer with a positive expression of estrogen and/or progesterone receptors makes for 75% of all cases of breast cancer. Such tumors, as a general rule, are less aggressive, have more favorable clinical course, better outcome and lesser chance of recurrence, in comparison with hormone-negative forms of a disease. Recently, the study of endocrine resistance has shown its clinical significance in possibility of finding ways and mechanisms to overcome tumor tolerance to treatment. This is supported by deeper understanding of molecular mechanisms leading to tolerance and development of new strategies, directed on improving treatment efficacy.


Key words

breast cancer, endocrine therapy, acquired resistance, mTOR inhibitors, cyclin-dependent kinase

Reference list

1. Krasilnikov M.A., Jykov N.V. Signalnii pyt mTOR: novaya mishen terapii opyholei. Sovremennaya onkologiya. 2010; (2): 9-16.


2. Yan Song, Yanni Hao, Alexander R. Macalalad et al. Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer. Breast Cancer: Basic and Clinical research 2015; (9):67-72.


3. Andrea Milani, Elena Geuna, Gloria Mittica. Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. World Journal of Clinical Oncology. 2014; (5): 990-1001.


4. Cynthia X. Ma, Tomás Reinert et al. Mechanisms of aromatase inhibitor resistance. Nature Reviews. Cancer. 2015; (15): 261-270.


5. Campone M, Yang H, Faust E, et al. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe. J Med Econ. 2014;17(12):837-845.


6. Baselga, J., Campone, M., Piccart, M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012; (366): 520-529.


7. Valentina Sini, Saverio Cinieri et al. Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. Critical Reviews in Oncology/Hematology. 2016;(100):57-68.


8. Bonneterre, J., Thurlimann, B., Robertson, J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. 2000. J. Clin. Oncol. (18): 3748-3757.


9. Buzdar, A.U., Jonat, W., Howell, A., et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer. 1998; (83): 1142-1152.


10. Buzdar, A., Hayes, D., El-Khoudary, A., et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res. Treat. 2002; (73): 161-175.


11. Dombernowsky, P., Smith, I., Falkson, G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrolacetate. J. Clin. Oncol. 1998 (16):453-461.


12. Finn, R.S., Crown, J.P., Lang, I., et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HE advanced breast cancer (BC). Cancer Res. 2012; (72): Supplement 3; SABCS12-S1-6


13. Robertson, J.F.R., Lindemann, J.P.O., Llombart-Cussac, A., et al. A comparison of fulvestrant 500mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the FIRST study. Cancer Res. 2010; (70); 24 Suppl, 76s.


14. Muss, H.B., Wells, H.B., Paschold, E.H., et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis?a phase III trial of the Piedmont Oncology Association. J. Clin. Oncol. 1988; (6):1098-1106.


15. Bergh, J., Jonsson, P.E., Lidbrink, E.K., et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J. Clin. Oncol. 2012; (30):1919-1925.


16. Di Leo, A., Jerusalem, G., Petruzelka, L., et al.Final analysis of overall survival for the Phase III confirm trial: fulvestrant 500 mg versus 250 mg. San Antonio Breast Cancer Symposium, 2012; S1-S4.


17. Hortobagyi, Gabriel N., Piccart-Gebhart Martine, J., RugoHope, S., et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. J. Clin. Oncol. 2013;(31)


18. Margariti, N., Fox, S.B., Bottini, A., Generali, D. Overcoming breast cancer drug resistance with mTOR inhibitors. Could it be a myth or a real possibility in theshort-termfuture? BreastCancerRes.Treat. 2011; (128): 599-606.


19. Mehta, R.S., Barlow, W.E., Albain, K.S., et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N. Engl. J. Med. 2012 (367): 435-444.


20. Turner, Nicholas C., Ro, Jungsil, Andre, Fabrice, et al. PALOMA3: a double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. J. Clin. Oncol. 2015; (33) (suppl; abstr LBA502).


21. Sanchez, C.G., Ma, C.X., Crowder, R.J., et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 2011; (13): R21.


22. Gupta S, Zhang J, Jerusalem G. et al. Association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor- positive, HER2-negative metastatic breast cancer: experience from the patient perspective. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):929-940.


23. Miguel Martin, Sara Lopez-Tarruella et al. Endocrine therapy for hormone treatment-naïve advanced breast cancer. The Breast. 2016; (28):161-166.


24. Di Leo A, Jerusalem G, Petruzelka L, et al: Final overall survival: Fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J. Natl. Cancer Inst. 2014 (106):djt337.


25. Nicolini A., Ferrari P., Kotlarova L. et al. The PI3K-AKt-mTOR pathway and new tools to prevent acquired hormone resistance in breast cancer. Curr Pharm Biotechnol 2015;(9):804-15


26. Wolff AC, Lazar AA, Bondarenko I, et al: Ran- domized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin. Oncology. 2013;(31):195-202.


27. Johnston SR: Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer: Cotargeting signaling pathways. J Natl Cancer Inst. 2015; (107): djv212,


28. Marta Bonotto, Lorenzo Gerratana et al. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis. 2017; (31): 114-120.


29. Murphy C.G., Dickler M.N. The role of CDK4/6 inhibition in breast cancer. Oncologist 2015;20(5):483-90.


30. Sonke G.S., Hart L.L., Campone M. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Research and Treatment. 2017; (25)